Back to results
US 2021/0332028 A1Published application
Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
AssigneeOrion Corporation
InventorsDavid JONAITIS, Oskari KARJALAINEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel hydrochloride salt forms of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide (I). Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
Claims15
A compound which is a hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)-cyclopropanesulfonamide (I).
Dependencies are inferred from the claim text.